On the HCPLive Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.
April 22nd 2024
Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.
Better Adherence Needed for Canadian Ulcerative Colitis Care Guidelines
The results show adherence to 6 quality indicators was linked to improvements in the post-intervention cohort with significant increases in C difficile testing, CRP testing, testing for latent tuberculosis, thromboprophylaxis, adequate corticosteroids prescription, and limitation of narcotics prescribed.
Both Ustekinumab, Vedolizumab Safe and Efficacious Treating Elderly Patients With IBD
The male gender was positively associated with a higher risk of serious infection at month 12 and penetrating disease behavior was positively associated with 12-month treatment persistence.